- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06561685
En studie av LY4050784 hos deltagare med avancerade eller metastaserande solida tumörer
En öppen multicenterstudie av LY4050784, en selektiv SMARCA2/BRM-hämmare, i avancerade solida tumörmaligniteter med SMARCA4/BRG1-förändringar
The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two parts - phase Ia (dose-escalation) and phase Ib (dose-optimization, dose-expansion). The study will last up to approximately 4 years.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
-
Bordeaux, Frankrike, 33 076
- Institut Bergonie
-
Paris, Frankrike, 75248
- Institut Curie
-
Villejuif, Frankrike, 94800
- Institut Gustave Roussy-Gustave Roussy Cancer Center -DITEP
-
-
-
-
California
-
Santa Monica, California, Förenta staterna, 90404
- UCLA
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80045
- University of Colorado Health Hospital
-
Denver, Colorado, Förenta staterna, 80218
- Sarah Cannon Research Institute at HealthOne
-
-
Florida
-
Lake Mary, Florida, Förenta staterna, 32746
- Florida Cancer Specialists ORLANDO/DDU
-
Miami, Florida, Förenta staterna, 33136
- University of Miami
-
-
Illinois
-
New Lenox, Illinois, Förenta staterna, 60451
- University of Chicago
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Förenta staterna, 02114
- Massachusetts General Hospital
-
-
New York
-
New York, New York, Förenta staterna, 10032
- Columbia University Medical Center
-
New York, New York, Förenta staterna, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Ohio
-
Columbus, Ohio, Förenta staterna, 43210
- Ohio State University Hospital
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37203
- Sarah Cannon Research Institute
-
Nashville, Tennessee, Förenta staterna, 37232-6307
- Vanderbilt-Ingram Cancer Center
-
Nashville, Tennessee, Förenta staterna, 37203
- SCRI Oncology Partners
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030-4009
- MD Anderson Cancer Center
-
-
Virginia
-
Fairfax, Virginia, Förenta staterna, 22031
- USO-Virginia Cancer Specialists, PC
-
-
Wisconsin
-
Milwaukee, Wisconsin, Förenta staterna, 53226
- Medical College of Wisconsin
-
-
-
-
-
Chūōku, Japan, 104-0045
- National Cancer Center Hospital
-
Kashiwa, Japan, 277-8577
- National Cancer Center Hospital East
-
Kōtō City, Japan, 135-8550
- The Cancer Institute Hospital of JFCR
-
Nagaizumi-cho,Sunto-gun, Japan, 411-8777
- Shizuoka Cancer Center
-
-
-
-
-
Barcelona, Spanien, 08035
- Hospital Universitari Vall d'Hebron
-
Madrid, Spanien, 28040
- South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz
-
-
-
-
-
Ilsandong-gu, Sydkorea, 10408
- National Cancer Center
-
Seoul, Sydkorea, 03722
- Severance Hospital, Yonsei University Health System
-
Suwon, Sydkorea, 16247
- The Catholic University of Korea, St. Vincent's Hospital
-
-
-
-
-
Berlin, Tyskland, 10117
- Charite-Universitatsmedizin Berlin
-
Essen, Tyskland, 45147
- Universitaetsklinikum Essen
-
Frankfurt am Main, Tyskland, 60488
- Krankenhaus Nordwest
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Have one of the following locally advanced or metastatic solid tumor malignancy with SMARCA4 (BRG1) alteration:
- Phase 1a dose escalation: Presence of any alteration in SMARCA4 (BRG1)
- Phase 1b expansion: Part A: Non-small Cell Lung Cancer (NSCLC) that is locally advanced and not suitable for definitive locoregional therapy, or metastatic with presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.
- Phase 1b expansion: Part B: Any tumor type (other than NSCLC) that has the presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.
- Phase 1b expansion: Part C: Non-small Cell Lung Cancer (NSCLC) that is locally advanced and not suitable for definitive locoregional therapy, or metastatic with presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.
-
Prior Systemic Therapy Criteria:
- Phase 1a dose escalation and Phase 1b (Part B): Participants who received all standard therapies for which the individual was deemed to be an appropriate candidate by the treating Investigator; or the individual is refusing the remaining most appropriate standard of care treatment; or there is no standard therapy available for the disease.
- Phase 1b expansion (Part A): Participants must have received at least one line of therapy for advanced or metastatic disease.
- Phase 1b expansion (Part C): Participants may be treatment naïve or have received therapy for advanced or metastatic disease
-
Measurability of disease
- Phase 1a dose escalation (excluding backfill): measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1)
- Phase 1a backfill and Phase 1b expansion: Measurable disease required as defined by RECIST v1.1
-
Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
Exclusion Criteria:
- Participants with known or likely loss of function alteration of SMARCA2 (BRM) or malignancy with known association with SMARCA2 (BRM) alterations
- Prior exposure to SMARCA2 (BRM) inhibitor(s) and/or degrader(s) (prior exposure may be permitted for dose escalation)
- Participants with known or suspected history of untreated or uncontrolled central nervous system (CNS) involvement
- Participants with history of increased risk of prolonged QT or significant arrythmia
- Significant cardiovascular disease
- Participants with active and/or treated for an additional primary malignancy within 2 years prior to enrolment
- Participants who are pregnant, breastfeeding or plan to breastfeed or expecting to conceive or father children during study or within 6 months after the last dose of study intervention
- Participants with history of active autoimmune diseases, history of allogenic stem cell/organ transplant or compromised immune system within past 2 years (Part C only)
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: LY4050784 (Phase 1a - Dose Escalation)
Escalating doses of LY4050784 administered orally. |
Oral |
|
Experimentell: LY4050784 (Phase 1b - Dose Optimization/Part A)
Comparing 2 or more doses (evaluated during dose escalation) of LY4050784 administered orally. |
Oral |
|
Experimentell: LY4050784 (Phase 1b - Dose Expansion/Part B)
LY4050784 administered orally. |
Oral |
|
Experimentell: LY4050784 (Phase 1b - Dose Expansion/Part C) Cohort C1
LY4050784 administered orally in combination in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. |
Oral Administered IV. |
|
Experimentell: LY4050784 (Phase 1b - Dose Expansion/Part C) Cohort C2a
LY4050784 administered orally in combination in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. |
Oral Administered IV. Administered IV. Administered IV. Administered IV. |
|
Experimentell: LY4050784 (Phase 1b - Dose Expansion/Part C) Cohort C2b
LY4050784 administered orally in combination in combination with pembrolizumab, paclitaxel/nab-paclitaxel and carboplatin administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. |
Oral Administered IV. Administered IV. Administered IV. Administered IV. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Phase Ia: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs)
Tidsram: Up to Approximately 48 Months or 4 Years
|
A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module |
Up to Approximately 48 Months or 4 Years
|
|
Phase 1a: To determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of LY4050784
Tidsram: Up to Approximately 48 Months or 4 Years
|
Number of participants with dose-limiting toxicities (DLTs) |
Up to Approximately 48 Months or 4 Years
|
|
Phase 1b: To assess the antitumor activity of LY4050784 Monotherapy: Overall response rate (ORR)
Tidsram: Up to Approximately 48 Months or 4 Years
|
ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) |
Up to Approximately 48 Months or 4 Years
|
|
Phase 1b (Dose optimization only): To confirm the RP2D/optimal dose based on safety and efficacy of LY4050784
Tidsram: Up to Approximately 48 Months or 4 Years
|
A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module, ORR and Duration of Response (DOR) per Investigator |
Up to Approximately 48 Months or 4 Years
|
|
Phase 1b (Combination cohorts/Part C): To assess the safety and tolerability of LY4050784 when administered in combination with other anticancer agents
Tidsram: Up to Approximately 48 Months or 4 Years
|
A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module |
Up to Approximately 48 Months or 4 Years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
För att utvärdera PK -egenskaperna för LY4050784 i kombinationskohorter: maximal koncentration (CMAX) PK: CMAX av LY4050784
Tidsram: Cykel 1 (dag 8)
|
Cykel 1 (dag 8)
|
|
|
För att utvärdera PK -egenskaperna för LY4050784 i kombinationskohorter: Tid till maximal koncentration (TMAX) PK: TMAX av LY4050784
Tidsram: Cykel 1 (dag 8)
|
Cykel 1 (dag 8)
|
|
|
För att utvärdera PK -egenskaperna för LY4050784 i kombinationskohorter: område under koncentrationen kontra tidskurva (AUC)
Tidsram: Cykel 1 (dag 8)
|
Cykel 1 (dag 8)
|
|
|
To characterize the pharmacokinetics (PK) properties of LY4050784: Maximum Concentration (Cmax)
Tidsram: Cycle 1 (Day 8)
|
PK: Cmax of LY4050784 |
Cycle 1 (Day 8)
|
|
To characterize the PK properties of LY4050784: Time to Maximum Concentration (Tmax)
Tidsram: Cycle 1 (Day 8)
|
PK: Tmax of LY4050784 |
Cycle 1 (Day 8)
|
|
To characterize the PK properties of LY4050784: Area under the concentration versus time curve (AUC)
Tidsram: Cycle 1 (Day 8)
|
PK: AUC of LY4050784 |
Cycle 1 (Day 8)
|
|
Phase Ia: To evaluate the preliminary antitumor activity of LY4050784: Overall response rate (ORR)
Tidsram: Up to Approximately 48 Months or 4 Years
|
ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) |
Up to Approximately 48 Months or 4 Years
|
|
To evaluate the preliminary antitumor activity of LY4050784: Duration of response (DOR)
Tidsram: Up to Approximately 48 Months or 4 Years
|
DOR per investigator assessed RECIST 1.1 |
Up to Approximately 48 Months or 4 Years
|
|
To evaluate the preliminary antitumor activity of LY4050784: Time to response (TTR)
Tidsram: Up to Approximately 48 Months or 4 Years
|
TTR per investigator assessed RECIST 1.1 |
Up to Approximately 48 Months or 4 Years
|
|
To evaluate the preliminary antitumor activity of LY4050784: Disease control rate (DCR)
Tidsram: Up to Approximately 48 Months or 4 Years
|
DCR per investigator assessed RECIST 1.1 |
Up to Approximately 48 Months or 4 Years
|
|
To evaluate the preliminary antitumor activity of LY4050784: Progression free survival (PFS)
Tidsram: Up to Approximately 48 Months or 4 Years
|
PFS per investigator assessed RECIST 1.1 |
Up to Approximately 48 Months or 4 Years
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Patologiska processer
- Neoplasmer efter plats
- Neoplasmer
- Luftvägssjukdomar
- Neoplasmer efter histologisk typ
- Lungsjukdomar
- Neoplasmer, körtel och epitel
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Neoplastiska processer
- Carcinom
- Neoplasmer, skivepitelceller
- Karcinom, bronkogent
- Bronkiella neoplasmer
- Patologiska tillstånd, tecken och symtom
- Lungneoplasmer
- Karcinom, skivepitel
- Neoplasma Metastas
- Karcinom, icke-småcellig lunga
- Adenocarcinom
- Aminosyror, peptider och proteiner
- Organiska kemikalier
- Heterocykliska föreningar
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Kolväten
- Cykloparaffiner
- Kolväten, alicyklisk
- Kolväten, cykliska
- Terpener
- Oorganiska kemikalier
- Klorföreningar
- Kväveföreningar
- Koordinationskomplex
- Guanin
- Hypoxantiner
- Purinoner
- Puriner
- Glutamater
- Aminosyror, sur
- Aminosyror
- Aminosyror, dikarboxyl
- Taxoids
- Cyklodekaner
- Gentare
- Hälsovårdsekonomi och organisationer
- Platinaföreningar
- Ekonomi
- Pemetrexed
- Karboplatin
- Paklitaxel
- Cisplatin
- pembrolizumab
- Skatter
Andra studie-ID-nummer
- 27191
- J5M-OX-JOXA (Annan identifierare: Eli Lilly and Company)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .